Abstract 2281
Background
TM is a useful tool that improves access to medical care for rural residents. However, factors that correlate with a positive TM experience are not well known. The study aims to determine TM experience in cancer patients and physicians, and to explore clinical and socio-economic factors (CSF) that are associated with a positive TM experience in patients.
Methods
In this cross-sectional study cancer patients on active treatment and physicians in the province of Saskatchewan, Canada completed a paper-based comprised of 32 items or an electronic survey of 18 items, respectively. Six point likert score was used. Logistic regression analysis was done to assess correlation between self-reported CSF and a positive TM experience. We present here preliminary results.
Results
Overall 25 physicians and 165 patients responded to the survey over a period of three months. Among physicians 69% were in practice for ≥10 yrs with M:F of 1.7:1. 94% were confident in their TM assessment, 58% felt that TM improve clinical efficiency, and 74% felt that doctor-patient rapport was unimpaired with TM. Of 165 patients with median age of 67 years (IQR 59-75) and M:F of 1.06:1, 60% were ≥65 yrs, 70% were married, and 82% had a dependent family member. 94% were born in Canada, 77% were Caucasian, 29% were working and 35% had annual income of < 40K. 67% had solid tumor, 46% reported having a curable cancer, 31% had surgery, 27% had radiation, and 62% had chemotherapy. 61% used TM first time. 90% felt that their needs were met, 91% felt that TM improved their quality of care, and 91% had a good experience. Overall, 83% patients vs. 45% physicians preferred TM to in-person clinic visit (P = 0.005). Only univariate analysis only age ≥65 was strongly associated with a positive TM experience, odd ratio 4.1 (1.2-13.8), p = 0.02. No other CSF including marital status, income, working status, dependent family member, and cancer type were significantly correlated with a positive TM experience.
Conclusions
This study supports a higher rate of positive TM experience in cancer patients and physicians. However, high preference of TM was noted among patient compared with physicians. Among various variables examined only older age was associated with a positive TM experience.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shahid Ahmed.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3317 - Circulating tumor DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met
Presenter: Rebecca Heist
Session: Poster Display session 1
Resources:
Abstract
3887 - First Real Life Data on Durvalumab after definitive concomitant ChemoRadiotherapy (cCRT) in unresectable Stage (St) III Non-Small Cell Lung Cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) Temporary Authorization of Use (ATU)
Presenter: Virginie Avrillon
Session: Poster Display session 1
Resources:
Abstract
682 - EGFR Inhibitor Versus Chemotherapy as Adjuvant Treatment for Locally-advanced EGFR-mutant Non-Small Cell Lung Cancer
Presenter: Peng Xie
Session: Poster Display session 1
Resources:
Abstract
2509 - Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: interim analysis of a Phase IIIb, multi-national, open-label study
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3300 - First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis
Presenter: Daniel SW Tan
Session: Poster Display session 1
Resources:
Abstract
2653 - A combined analysis of two Phase IIIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3663 - Impact of plasma EGFR mutation fractions on response to first generation tyrosine-kinase inhibitor in treatment of naïve non-small cell lung cancer patients
Presenter: Xiaohong Wang
Session: Poster Display session 1
Resources:
Abstract
5921 - Definition of an afatinib trough concentration threshold in the treatment of NSCLC
Presenter: Stephane Bouchet
Session: Poster Display session 1
Resources:
Abstract
2852 - A Phase Ib Trial of Neoadjuvant Chemoradiotherapy and Durvalumab(MEDI4736) for Potentially Resectable stage III Non-Small Cell Lung Cancer (NSCLC)
Presenter: Beung chul AHN
Session: Poster Display session 1
Resources:
Abstract
3273 - Low expression of Notch1 and combined Notch1/HES1 are associated with adverse survival factor for limited stage small cell lung cancer
Presenter: Jinsoo Lee
Session: Poster Display session 1
Resources:
Abstract